Moderna (MRNA) and Merck (MRK) announce 5yr data for Intismeran in combination with Keytruda
Importance
Level 1
- In this pre-planned analysis, adjuvant treatment with intismeran autogene in combination with Keytruda continued to demonstrate sustained and clinically meaningful improvement in the study's primary endpoint, recurrence-free survival, RFS, reducing the risk of recurrence or death by 49% compared to KEYTRUDA alone.
#GERMANY#EUROPE#MERCK & CO INC#MRK.US#MERCK KGAA#EQUITIES#EU SESSION#BIOTECHNOLOGY#PHARMACEUTICALS#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#DAX 40 INDEX#NASDAQ 100 INDEX#MRK#MODERNA INC#MRNA#US EQUITIES